Challenge: A multinational investment firm was interested in performing an objective, third party analysis of the cell and gene therapy

Situation: An emerging biotech desired to connect with potential partners to explore out licensing opportunities during BIO 2020. The client,

“View of the Future.” It’s critical to understand the current landscape for each client’s service offerings, but understanding what respondents

Locus Biosciences is revolutionizing the treatment of bacterial disease using its CRISPR-Cas3 technology to kill targeted bacteria while leaving the

The Biopharma CEO Confidence Index is a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’s

Situation: An innovative preclinical CRO with multiple disruptive service offerings retained Kineticos to conduct an evaluation of each of their

Situation: A global biopharma company was interested in a comprehensive evaluation of the 503B compounding pharmacy market. The client was

Written by Abe Maingi, VP of Precision Medicine, Kineticos Confirmation bias is our tendency to search for and favor all

Kineticos conducted primary research via KOLs and an online survey to give our client qualitative and quantitative data to support

The final part of the discussion between Kineticos’ Operating Executive, Steve Buckanavage and Precision Biosciences’ CMO, Christopher Heery M.D., covers